{"title":"ECMHA-PP: A Breast Cancer Prognosis Prediction Model Based on Energy-Constrained Multi-Head Self-Attention.","authors":"Fan Zhang, Chaoyang Liu, Xinhong Zhang","doi":"10.1002/prca.202400035","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Breast cancer is a significant threat to women's health. Precise prognosis prediction for breast cancer can help doctors implement more rational treatment strategies. Artificial intelligence can assist doctors in decision-making and enhance prediction accuracy.</p><p><strong>Experimental design: </strong>In this paper, a deep learning model ECMHA-PP (Energy Constrained Multi-Head Self-Attention based Prognosis Prediction) is proposed to predict the prognosis of breast cancer. ECMHA-PP utilizes patients' clinical data and extracts features through a cross-position mix and a channel mix multi-layer perceptron. Then, it incorporates an energy-constrained multi-head self-attention layer to improve feature extraction capability. The source code of ECMHA-PP has been hosted on GitHub and is available at https://github.com/xiaoliu166370/ECMHA-PP.</p><p><strong>Results: </strong>To evaluate our proposed method, prognostic prediction experiments were performed on the METABRIC dataset, yielding outstanding results with an average accuracy of 93.0% and an average area under the curve of 0.974. To further validate the model's performance, we conducted tests on another independent dataset, BRCA, achieving an accuracy of 87.6%.</p><p><strong>Conclusions and clinical relevance: </strong>In comparison with other widely used advanced methods, ECMHA-PP demonstrated higher comprehensive performance, making it a reliable prognostic prediction model for breast cancer. Given its robust feature extraction and prediction capabilities.</p>","PeriodicalId":20571,"journal":{"name":"PROTEOMICS – Clinical Applications","volume":" ","pages":"e202400035"},"PeriodicalIF":2.1000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"PROTEOMICS – Clinical Applications","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1002/prca.202400035","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/2 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"BIOCHEMICAL RESEARCH METHODS","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: Breast cancer is a significant threat to women's health. Precise prognosis prediction for breast cancer can help doctors implement more rational treatment strategies. Artificial intelligence can assist doctors in decision-making and enhance prediction accuracy.
Experimental design: In this paper, a deep learning model ECMHA-PP (Energy Constrained Multi-Head Self-Attention based Prognosis Prediction) is proposed to predict the prognosis of breast cancer. ECMHA-PP utilizes patients' clinical data and extracts features through a cross-position mix and a channel mix multi-layer perceptron. Then, it incorporates an energy-constrained multi-head self-attention layer to improve feature extraction capability. The source code of ECMHA-PP has been hosted on GitHub and is available at https://github.com/xiaoliu166370/ECMHA-PP.
Results: To evaluate our proposed method, prognostic prediction experiments were performed on the METABRIC dataset, yielding outstanding results with an average accuracy of 93.0% and an average area under the curve of 0.974. To further validate the model's performance, we conducted tests on another independent dataset, BRCA, achieving an accuracy of 87.6%.
Conclusions and clinical relevance: In comparison with other widely used advanced methods, ECMHA-PP demonstrated higher comprehensive performance, making it a reliable prognostic prediction model for breast cancer. Given its robust feature extraction and prediction capabilities.
期刊介绍:
PROTEOMICS - Clinical Applications has developed into a key source of information in the field of applying proteomics to the study of human disease and translation to the clinic. With 12 issues per year, the journal will publish papers in all relevant areas including:
-basic proteomic research designed to further understand the molecular mechanisms underlying dysfunction in human disease
-the results of proteomic studies dedicated to the discovery and validation of diagnostic and prognostic disease biomarkers
-the use of proteomics for the discovery of novel drug targets
-the application of proteomics in the drug development pipeline
-the use of proteomics as a component of clinical trials.